Warburg Pincus Partners II (Cayman), LP

Director Pincus & Co. Warburg sells entire 19,102,952 share stake in SHC for $289.8M at $15.17; stock down 4.7% in 30 days, -23.1% from 52-week high.

Pincus & Co. Warburg liquidated his complete position in Sotera Health—19,102,952 shares for $289,753,575.94 total value—on 2026-05-13, leaving zero post-transaction holdings. The sale occurred at $15.17 while the stock has since declined to $15.27 (current price is -23.1% from its 52-week high of $19.85) and has fallen 4.7% in the 30 days since the transaction. Across his prior five trades specifically at SHC, Pincus achieved well-timed exits on 2 of 5 occasions (measured by negative 90-day returns post-sale). The complete exit warrants investor attention given the large absolute dollar value and the concentration risk this insider was previously carrying.

Warburg Pincus sells 15,000,000 SHC shares for $229.0M at $15.27; exits -44.0% of position as stock trades -27.3% from 52-week high

Warburg Pincus substantially reduced its SHC position by 15,000,000 shares (44.0% of prior holdings) on 2026-03-06 at $15.27 per share, generating $229,050,000.00 in proceeds. The timing is notable: the sale occurred when the stock was -27.3% below its 52-week high and has declined -20.8% in the 30 days since the transaction and -16.8% over 90 days. Across his prior SHC trades (5 prior transactions), 2 of 4 measurable historical sales showed negative 90-day returns after sale (well-timed outcomes), though the other 2 showed positive returns. The current price of $14.06 sits 7.9% below the execution price, partially validating this exit point relative to recent momentum. At a P/E of 45.35 and 5.7% annual revenue growth, the company commands a premium valuation that may weigh on near-term upside.

Warburg Pincus sells 4,250,000 BANC shares at $20.10; reduces stake 61.7%, retains 2,640,244 shares post-transaction.

Warburg Pincus LLC, a Director of Banc of California, executed a substantial open-market sale of 4,250,000 shares at $20.10 on 2026-02-13, reducing its position by 61.7% from 6,890,244 to 2,640,244 shares and realizing $85,425,000.00 in proceeds. The sale occurred with the stock trading -4.7% below its 52-week high of $21.10 and follows recent price momentum of +18.9% over 90 days, suggesting the insider capitalized on a near-peak valuation. The company's fundamentals remain solid—net income of $69,629,000.00 and annual revenue growth of +24.1%—yet this outsized reduction in a major director's stake, combined with Warburg Pincus's prior five sales at BANC all executed within a 12-day window (February 2–13), signals a deliberate and material shift in the insider's exposure to the company. The cross-ticker track record shows a 30.77% well-timed rate on prior sales, though same-ticker outcomes at BANC are not yet measurable, leaving the strategic intent of this concentrated exit unclear pending 90-day post-transaction price performance.

Warburg Pincus LLC completely exits 11.85M shares ($237.0M) at $20.00 on 2026-02-02

Warburg Pincus LLC, a director of BANC OF CALIFORNIA, INC., executed 3 separate sales totaling 11,850,000 shares for $237,000,000.00, reducing holdings to 0 shares—a complete exit of its position on 2026-02-02. The blended average price of $20.00 compares to a current price of $20.13 and a 52-week high of $21.10, placing the transaction near the recent trading range but not at the absolute peak. The company's fundamentals remain solid with Annual revenue growth of +24.1%, a P/E of 14.59, and recent quarterly revenue of $466,826,000.00 and net income of $69,629,000.00. Prior sales by this insider at BANC on 2025-09-08 each showed positive 30d and 90d returns (+8.1% and +16.6%), meaning those sales proved poorly timed as the stock rose afterward; notably, neither of the 2 measurable prior sales at this ticker achieved a negative 90-day return (0 of 2 well-timed). The complete liquidation of a director-level stake warrants attention to whether fundamentals or capital allocation strategy has shifted, particularly given the absence of any public disclosure flags that would explain the exit timing or intent.

WARBURG PINCUS & CO. sells 9,720,000 shares of SHC at $16.33; holdings drop to 34.10M (-22.2%)

WARBURG PINCUS & CO. executed a substantial sale of 9,720,000 shares at $16.33 on 2025-12-03, reducing its stake from 43,822,952 to 34,102,952 shares and cutting holdings by 22.2%. The transaction was completed at $16.33, which is near the current price of $16.75 and well within the 52-week range of $9.80–$17.48 (within 4.2% of the 52-week high). At the same-ticker level, the insider's prior two measurable sales at SHC (both on 2025-09-05) saw the stock subsequently post positive 90-day returns of +9.6%, indicating those earlier exits were not well-timed. The cross-ticker track record shows a 66.67% well-timed rate on 9 prior sells, though that metric does not predict performance at this specific ticker. Given the substantial reduction in holdings, near-peak pricing at transaction time, and the company's elevated P/E of 83.75 against modest revenue growth of 4.9%, the transaction merits investor attention but remains within normal portfolio management parameters.

Warburg Pincus sells 9,720,000 SHC shares for $158.7M; holdings drop 22.2% to 34.10M

Warburg Pincus (Director) executed a substantial sale of 9,720,000 shares at $16.33 on 2025-12-03, reducing holdings by 22.2% to 34,102,952 shares and generating $158,727,600.00 in proceeds. This represents a meaningful reduction in the director's position at Sotera Health, which trades near its 52-week high of $17.48 at a current price of $16.75. The transaction occurs at a valuation where the company's P/E of 83.75 and recent quarterly revenue of $311,312,000.00 with net income of $48,400,000.00 merit scrutiny; the director's multi-transaction history at SHC shows that 0 of 2 prior measurable sells were well-timed (stock rose 9.6% over 90 days following the September sells), suggesting the insider's exits at this ticker have not anticipated subsequent declines. Investors should monitor whether this large exit—combined with the company's rich valuation and modest 4.9% annual revenue growth—reflects evolving confidence in the equity or is driven by other portfolio considerations.

Warburg Pincus sold 18,000,000 shares of SHC at $15.65 for $281.7M, reducing stake by 29.1%

Warburg Pincus executed a substantial $281.7M divestiture of 18,000,000 shares, reducing its SHC holding from 61.82M to 43.82M shares (a 29.1% reduction). This represents a meaningful reduction in the insider's position size at a price of $15.65, which sits 3.8% below the 52-week high of $16.90. The sale's significance is underscored by the insider's track record across all tickers: its 7 prior open-market sells showed a 100.00% well-timed rate at the 90-day mark, and at SHC specifically, 2 of 2 prior sales were well-timed at 90 days. However, current context matters—the stock has appreciated 3.7% over 30 days and 3.1% over 90 days, and trades at a P/E of 81.25 against annual revenue growth of 4.9%, suggesting elevated valuation multiples relative to growth. Investors should monitor whether this large, multi-year stake reduction signals confidence in near-term valuations or a fundamental reassessment of the company's outlook.

Warburg Pincus LLC sells 5,650,000 shares of BANC for $92,547,000.00, reducing stake by 64.2%

Warburg Pincus LLC, a director, executed 2 separate sales totaling 5,650,000 shares for $92,547,000.00 at $16.38 per share on 2025-09-05 and 2025-09-08, exiting 64.2% of its prior 8,797,470 shares and leaving a post-transaction holding of 3,147,470 shares. The sales occurred as BANC's stock trades at $16.79 (current), near its 52-week high of $17.77 with 30-day momentum of +15.5%, and the company shows solid fundamentals including $453,142,000.00 in quarterly revenue, $28,385,000.00 in net income, and 24.1% annual revenue growth. Across Warburg Pincus's entire cross-ticker open-market history, prior sells have averaged positive 90-day returns of 8.1% with a 40.00% well-timed rate; however, at this specific ticker (BANC), there are no prior measurable outcomes to establish a pattern. The substantial reduction in stake size and timing near recent price strength merit monitoring for any signals regarding the director's forward confidence in the company.

Warburg Pincus sells 12.00M SHC shares at $15.11, reducing stake 16.3% to 61.82M; prior 4 sales at this ticker 100% well-timed at 90-day mark

Warburg Pincus sold 12,000,000 shares of Sotera Health on 2025-09-05 at $15.11, a material 16.3% reduction in holdings to 61,822,952 shares, representing $181,332,000 in transaction value. This transaction is noteworthy because the insider's prior 4 measurable sales at the same ticker (2024-09-06 and 2024-03-04) were all well-timed at the 90-day mark, with negative returns of -13.7% and -21.9% respectively—consistent with a pattern of selling before declines. Additionally, across his broader cross-ticker portfolio, Warburg Pincus achieved a 100.00% well-timed rate on 5 prior sells, suggesting consistent ability to exit positions ahead of unfavorable price action. The current stock price of $15.81 sits -6.5% from the 52-week high, and the 30-day momentum is strong at +13.2%, yet the historical pattern at this ticker signals that the insider may be exiting ahead of further weakness that would emerge over the 90-day window.